Myocarditis Following SARS-CoV2 mRNA Vaccination Against COVID-19

Q: What are the key findings of this study?

SARS-CoV-2 mRNA vaccination triggers rare, mild myocarditis in 1 to 5 per 100,000 vaccinees, with an adjusted HR of 5.24 (95% CI 2.47-11.12) for mRNA-1273 in 12- to 39-year-olds.

Q: What is the clinical evidence from this study?

Study design: Editorial. Population: COVID-19 mRNA vaccine-associated myocarditis. Intervention: SARS-CoV-2 mRNA vaccination (mRNA-1273 and BNT162b2) vs. Unvaccinated individuals or pre-COVID historical controls. Primary outcome: Acute myocarditis within 28 days of mRNA-1273 vaccination among 12- to 39-year-olds (HR 5.24, 95% CI 2.47-11.12).

Stephane R B Heymans; Dana K. Dawson; Valentı́n Fuster; Marco Metra; Carlo Gabriele Tocchetti

doi:10.1016/j.jacc.2022.08.003

September 26, 2022Journal of the American College of CardiologyOpen Access

Myocarditis Following SARS-CoV2 mRNA Vaccination Against COVID-19

View Full Paper

Ask AI

Bookmark

Share

Key result

mRNA-1273 vaccination linked to ~5.2-fold higher myocarditis risk in younger recipients.

HR 5.24
95% CI 2.47-11.12

PICO

P

Population

Individuals receiving SARS-CoV-2 mRNA vaccines (Moderna mRNA-1273 and Pfizer-BioNTech BNT162b2), with emphasis on young men aged 12 to 39 years followed within 28 days of vaccination.

E

Exposure / Comparator

SARS-CoV-2 mRNA vaccination (mRNA-1273 and BNT162b2) vs Unvaccinated individuals or pre-COVID historical controls

O

Primary Outcome

Acute myocarditis within 28 days of mRNA-1273 vaccination among 12- to 39-year-olds — HR 5.24 (2.47-11.12)

Main Result

Hazard Ratio: 5.24 (95% CI 2.47–11.12)

Limitations

All cited studies establish only a temporal relationship between vaccination and myocarditis without definite causality
Minimal diagnostic criteria (symptoms, ECG changes, cardiac injury biomarkers) may lead to overestimation of cases
Cardiac magnetic resonance imaging was performed in only 30% of patients with troponin elevation, potentially causing underestimation
Endomyocardial biopsies were performed in <5% of cases, making the diagnosis less certain
Recommendations regarding longer interdose intervals and non-mRNA boosters are based solely on retrospective observations

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

May prompt enhanced myocarditis surveillance after mRNA-1273 in youth; leaves open need for prospective causal confirmation.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Heymans et al. (2022) conducted an editorial in COVID-19 mRNA vaccine-associated myocarditis. SARS-CoV-2 mRNA vaccination (mRNA-1273 and BNT162b2) vs. Unvaccinated individuals or pre-COVID historical controls was evaluated on Acute myocarditis within 28 days of mRNA-1273 vaccination among 12- to 39-year-olds (HR 5.24, 95% CI 2.47-11.12). SARS-CoV-2 mRNA vaccination triggers rare, mild myocarditis in 1 to 5 per 100,000 vaccinees, with an adjusted HR of 5.24 (95% CI 2.47-11.12) for mRNA-1273 in 12- to 39-year-olds.

synapsesocial.com/papers/6adb25b98ba646412317423c https://doi.org/10.1016/j.jacc.2022.08.003

View Full Paper

Ask AI

Bookmark

Share

Myocarditis Following SARS-CoV2 mRNA Vaccination Against COVID-19

PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Myocarditis Following SARS-CoV2 mRNA Vaccination Against COVID-19

PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading